» Articles » PMID: 16108840

Relationship of Non-alcoholic Hepatic Steatosis to Cortisol Secretion in Diet-controlled Type 2 Diabetic Patients

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2005 Aug 20
PMID 16108840
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To examine the association of non-alcoholic hepatic steatosis (HS) with the activity of the hypothalamo-pituitary-adrenal (HPA) axis in Type 2 diabetic individuals.

Methods: The activity of the HPA axis, as measured by 24-h urinary free cortisol (UFC) excretion and serum cortisol levels after 1.0 mg dexamethasone, was measured in 40 diet-controlled, predominantly overweight, Type 2 diabetic patients with non-alcoholic HS and in 40 diabetic patients without HS who were comparable for age, sex and body mass index (BMI).

Results: Subjects with non-alcoholic HS had significantly higher 24-h UFC excretion (191 +/- 4 vs. 102 +/- 3 nmol/24 h; P < 0.001) and post-dexamethasone cortisol concentrations (29.1 +/- 2 vs. 14.4 +/- 1 nmol/l; P < 0.001) than those without HS. Patients with HS had significantly higher values for HOMA insulin resistance score, plasma triglycerides and liver enzymes. Age, sex, BMI, waist-hip ratio (WHR), diabetes duration, HbA1c, LDL-cholesterol and blood pressure values were not different between the groups. The differences in urinary and serum cortisol concentrations between the groups remained significant after adjustment for age, sex, BMI, WHR, HOMA insulin resistance score, plasma triglycerides, HbA1c and liver enzymes. In multiple logistic regression analyses, 24-h UFC or serum cortisol concentrations (P < 0.05 and P = 0.02, respectively), along with age and HOMA insulin resistance, predicted the presence of HS, independently of potential confounders.

Conclusions: These results demonstrate that non-alcoholic HS is closely associated with a subtle, chronic overactivity of the HPA axis in diet-controlled Type 2 diabetic individuals.

Citing Articles

Pathophysiology of NASH in endocrine diseases.

Gariani K, Jornayvaz F Endocr Connect. 2021; 10(2):R52-R65.

PMID: 33449917 PMC: 7983516. DOI: 10.1530/EC-20-0490.


Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders.

Lin Y, Zhang Z, Wang S, Cai J, Guo J Rev Endocr Metab Disord. 2020; 21(4):421-429.

PMID: 32889666 DOI: 10.1007/s11154-020-09586-1.


NAFLD Aggravates Septic Shock Due to Inadequate Adrenal Response and 11β-HSDs Dysregulation in Rats.

Huang H, Tsai M, Lee F, Lin T, Chang C, Chuang C Pharmaceutics. 2020; 12(5).

PMID: 32354071 PMC: 7285211. DOI: 10.3390/pharmaceutics12050403.


Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma.

Ragucci E, Nguyen D, Lamerson M, Moraitis A Case Rep Endocrinol. 2018; 2017:6161348.

PMID: 29348947 PMC: 5733994. DOI: 10.1155/2017/6161348.


The impact of cortisol in steatotic and non-steatotic liver surgery.

Cornide-Petronio M, Bujaldon E, Mendes-Braz M, Avalos de Leon C, Jimenez-Castro M, Alvarez-Mercado A J Cell Mol Med. 2017; 21(10):2344-2358.

PMID: 28374452 PMC: 5618669. DOI: 10.1111/jcmm.13156.